Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $45.1 million.

  • Ultragenyx Pharmaceutical's Change in Accured Expenses rose 31711.96% to $45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.4 million, marking a year-over-year increase of 8819.71%. This contributed to the annual value of $47.0 million for FY2024, which is 511553.83% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Change in Accured Expenses of $45.1 million as of Q3 2025, which was up 31711.96% from -$9.7 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Change in Accured Expenses ranged from a high of $57.4 million in Q2 2022 and a low of -$48.5 million during Q1 2025
  • Moreover, its 5-year median value for Change in Accured Expenses was $11.8 million (2023), whereas its average is $7.7 million.
  • Data for Ultragenyx Pharmaceutical's Change in Accured Expenses shows a peak YoY increase of 45002.9% (in 2021) and a maximum YoY decrease of 33845.44% (in 2021) over the last 5 years.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Change in Accured Expenses (Quarter) stood at $30.4 million in 2021, then dropped by 9.75% to $27.4 million in 2022, then tumbled by 37.56% to $17.1 million in 2023, then skyrocketed by 170.85% to $46.4 million in 2024, then decreased by 2.72% to $45.1 million in 2025.
  • Its Change in Accured Expenses was $45.1 million in Q3 2025, compared to -$9.7 million in Q2 2025 and -$48.5 million in Q1 2025.